Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2022-11-10 18:04:37
Oslo, Norway, 10 November 2022
Reference is made to the stock exchange announcement by Nordic Nanovector ASA
("Nordic Nanovector" or the "Company") on 9 November 2022 announcing that the
Company has entered into a merger agreement with all shareholders of APIM
Therapeutics AS to combine the companies in an all-stock transaction. Completion
of the transaction is dependent on the approval by the General Meeting of the
Company.
Nordic Nanovector hereby calls for an Extraordinary General Meeting in the
Company to be held on 1 December 2022, at 10:00 hours CET at Advokatfirmaet
Selmer, Tjuvholmen Allé 1, 0252 Oslo. The full notice with appendices is
attached. The notice and the documents to which it refers are also available on
www.nordicnanovector.com.
Shareholders wishing to attend the Extraordinary General Meeting, in person or
by proxy, must complete and return the attendance form or power of attorney form
attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166
Sentrum, N-0107 Oslo, or by e-mail to nis@nordea.com no later than 29 November
2022, 16:00 CET. Attendance or proxies may also be registered electronically
through Euronext Securities Oslo (formerly VPS) Investor Services.
For further information, please contact:
IR enquiries
Malene Brondberg, interim CEO and CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company's pipeline includes:
· Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma
(NHL)